Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2024 08:30 ET | Source: Entera Bio Ltd.

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the...
March 26, 2024 08:30 ET | Source: Entera Bio Ltd.

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American...
March 20, 2024 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive...
March 08, 2024 16:05 ET | Source: Entera Bio Ltd.

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results...
March 04, 2024 08:30 ET | Source: Entera Bio Ltd.

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that it received...
January 30, 2024 08:30 ET | Source: Entera Bio Ltd.

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

JERUSALEM, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced...
January 03, 2024 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

JERUSALEM, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced...
December 26, 2023 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

JERUSALEM, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced...
November 29, 2023 08:30 ET | Source: Entera Bio Ltd.

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform

JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reported...
November 14, 2023 07:30 ET | Source: Entera Bio Ltd.

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right